APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antisense oligonucleotides (ASO) Drug and siRNA Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Research Report 2026

23 December 2025145 pages

Choose your research edition.

Industry ResearchAntisense oligonucleotides (ASO) Drug and siRNA Drug Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Antisense oligonucleotides (ASO) Drug and siRNA Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antisense oligonucleotides (ASO) Drug and siRNA Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antisense oligonucleotides (ASO) Drug and siRNA Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antisense oligonucleotides (ASO) Drug and siRNA Drug include Novartis, Novo Nordisk, Biogen, AstraZeneca, WAVElife, Therapeutics, The WhiteOak Group, Inc., Sylentis and Sirnaomics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antisense oligonucleotides (ASO) Drug and siRNA Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Antisense oligonucleotides (ASO) Drug and siRNA Drug Market by Company

Novartis

Novo Nordisk

Biogen

AstraZeneca

WAVElife

Therapeutics

The WhiteOak Group, Inc.

Sylentis

Sirnaomics

Silence

Secarna

Sarepta Therapeutics

Quark Pharmaceuticals

ProQR

Miragen Therapeutics

Ionis

Genzyme

Exicure

Dicerna

Avidity Biosciences

Arrowhead

Alnylam

Akcea

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Type

Antisense Oligonucleotides (ASO) Drug

siRNA Drug

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Application

Chronic Liver Disease

Protein Deposition Disease

Single Gene Rare Disease

Others

Antisense oligonucleotides (ASO) Drug and siRNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense oligonucleotides (ASO) Drug and siRNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense oligonucleotides (ASO) Drug and siRNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2021-2026) Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2027-2032) Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2021-2026) Table 11. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2027-2032) Table 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2021-2026) Table 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2027-2032) Table 18. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends Table 19. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Drivers Table 20. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Opportunities and Challenges Table 21. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints Table 22. Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Players (2021-2026) Table 24. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Headquarters and Area Served Table 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 48. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 49. Novartis Recent Developments Table 50. Novo Nordisk Company Information Table 51. Novo Nordisk Business Overview Table 52. Novo Nordisk Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 53. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 54. Novo Nordisk Recent Developments Table 55. Biogen Company Information Table 56. Biogen Business Overview Table 57. Biogen Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 58. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 59. Biogen Recent Developments Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 63. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 64. AstraZeneca Recent Developments Table 65. WAVElife Company Information Table 66. WAVElife Business Overview Table 67. WAVElife Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 68. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 69. WAVElife Recent Developments Table 70. Therapeutics Company Information Table 71. Therapeutics Business Overview Table 72. Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 73. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 74. Therapeutics Recent Developments Table 75. The WhiteOak Group, Inc. Company Information Table 76. The WhiteOak Group, Inc. Business Overview Table 77. The WhiteOak Group, Inc. Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 78. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 79. The WhiteOak Group, Inc. Recent Developments Table 80. Sylentis Company Information Table 81. Sylentis Business Overview Table 82. Sylentis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 83. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 84. Sylentis Recent Developments Table 85. Sirnaomics Company Information Table 86. Sirnaomics Business Overview Table 87. Sirnaomics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 88. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 89. Sirnaomics Recent Developments Table 90. Silence Company Information Table 91. Silence Business Overview Table 92. Silence Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 93. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 94. Silence Recent Developments Table 95. Secarna Company Information Table 96. Secarna Business Overview Table 97. Secarna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 98. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 99. Secarna Recent Developments Table 100. Sarepta Therapeutics Company Information Table 101. Sarepta Therapeutics Business Overview Table 102. Sarepta Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 103. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 104. Sarepta Therapeutics Recent Developments Table 105. Quark Pharmaceuticals Company Information Table 106. Quark Pharmaceuticals Business Overview Table 107. Quark Pharmaceuticals Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 108. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 109. Quark Pharmaceuticals Recent Developments Table 110. ProQR Company Information Table 111. ProQR Business Overview Table 112. ProQR Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 113. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 114. ProQR Recent Developments Table 115. Miragen Therapeutics Company Information Table 116. Miragen Therapeutics Business Overview Table 117. Miragen Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 118. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 119. Miragen Therapeutics Recent Developments Table 120. Ionis Company Information Table 121. Ionis Business Overview Table 122. Ionis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 123. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 124. Ionis Recent Developments Table 125. Genzyme Company Information Table 126. Genzyme Business Overview Table 127. Genzyme Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 128. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 129. Genzyme Recent Developments Table 130. Exicure Company Information Table 131. Exicure Business Overview Table 132. Exicure Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 133. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 134. Exicure Recent Developments Table 135. Dicerna Company Information Table 136. Dicerna Business Overview Table 137. Dicerna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 138. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 139. Dicerna Recent Developments Table 140. Avidity Biosciences Company Information Table 141. Avidity Biosciences Business Overview Table 142. Avidity Biosciences Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 143. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 144. Avidity Biosciences Recent Developments Table 145. Arrowhead Company Information Table 146. Arrowhead Business Overview Table 147. Arrowhead Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 148. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 149. Arrowhead Recent Developments Table 150. Alnylam Company Information Table 151. Alnylam Business Overview Table 152. Alnylam Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 153. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 154. Alnylam Recent Developments Table 155. Akcea Company Information Table 156. Akcea Business Overview Table 157. Akcea Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) & (US$ Million) Table 158. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio Table 159. Akcea Recent Developments Table 160. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Image Figure 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type: 2025 VS 2032 Figure 7. Antisense Oligonucleotides (ASO) Drug Product Figure 8. siRNA Drug Product Figure 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application: 2025 VS 2032 Figure 11. Chronic Liver Disease Product Figure 12. Protein Deposition Disease Product Figure 13. Single Gene Rare Disease Product Figure 14. Others Product Figure 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region: 2025 VS 2032 Figure 18. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Players in 2025 Figure 19. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturers Established Date Figure 20. Global Top 5 and 10 Antisense oligonucleotides (ASO) Drug and siRNA Drug Players Market Share by Revenue in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 24. United States Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 27. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 29. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Spain Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Netherlands Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Nordic Countries Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 39. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 44. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. China Taiwan Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2021-2032) Figure 49. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Chile Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Colombia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Peru Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Novartis Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 55. Novo Nordisk Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 56. Biogen Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 57. AstraZeneca Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 58. WAVElife Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 59. Therapeutics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 60. The WhiteOak Group, Inc. Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 61. Sylentis Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 62. Sirnaomics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 63. Silence Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 64. Secarna Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 65. Sarepta Therapeutics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 66. Quark Pharmaceuticals Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 67. ProQR Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 68. Miragen Therapeutics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 69. Ionis Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 70. Genzyme Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 71. Exicure Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 72. Dicerna Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 73. Avidity Biosciences Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 74. Arrowhead Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 75. Alnylam Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026) Figure 76. Akcea Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)

Scope & coverage.

Types
  • Antisense Oligonucleotides (ASO) Drug
  • siRNA Drug
Applications
  • Chronic Liver Disease
  • Protein Deposition Disease
  • Single Gene Rare Disease
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Biogen
  • AstraZeneca
  • WAVElife
  • Therapeutics
  • The WhiteOak Group, Inc.
  • Sylentis
  • Sirnaomics
  • Silence
  • Secarna
  • Sarepta Therapeutics
  • Quark Pharmaceuticals
  • ProQR
  • Miragen Therapeutics
  • Ionis
  • Genzyme
  • Exicure
  • Dicerna
  • Avidity Biosciences
  • Arrowhead
  • Alnylam
  • Akcea

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Antisense Oligonucleotides (ASO) Drug
  5. 2.2.3 siRNA Drug
  6. 2.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Chronic Liver Disease
  9. 2.3.3 Protein Deposition Disease
  10. 2.3.4 Single Gene Rare Disease
  11. 2.3.5 Others
  12. 2.4 Assumptions and Limitations
3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Breakdown Data by Type
  1. 3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size by Type (2021-2026)
  2. 3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Type (2027-2032)
4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Breakdown Data by Application
  1. 4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size by Application (2021-2026)
  2. 4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Perspective (2021-2032)
  2. 5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Growth Trends by Region
  3. 5.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size by Region (2021-2026)
  5. 5.2.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Region (2027-2032)
  6. 5.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Dynamics
  7. 5.3.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
  8. 5.3.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
  9. 5.3.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
  10. 5.3.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Revenue
  2. 6.1.1 Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Revenue (2021-2026)
  3. 6.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug Head Office and Area Served
  6. 6.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Players, Product Type & Application
  7. 6.5 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturers Established Date
  8. 6.6 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  2. 7.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  4. 7.4 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  2. 8.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  4. 8.4 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  2. 9.2 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  2. 10.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  4. 10.4 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2021-2032)
  2. 11.2 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Novartis
  2. 12.1.1 Novartis Company Information
  3. 12.1.2 Novartis Business Overview
  4. 12.1.3 Novartis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  5. 12.1.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  6. 12.1.5 Novartis Recent Developments
  7. 12.2 Novo Nordisk
  8. 12.2.1 Novo Nordisk Company Information
  9. 12.2.2 Novo Nordisk Business Overview
  10. 12.2.3 Novo Nordisk Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  11. 12.2.4 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  12. 12.2.5 Novo Nordisk Recent Developments
  13. 12.3 Biogen
  14. 12.3.1 Biogen Company Information
  15. 12.3.2 Biogen Business Overview
  16. 12.3.3 Biogen Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  17. 12.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  18. 12.3.5 Biogen Recent Developments
  19. 12.4 AstraZeneca
  20. 12.4.1 AstraZeneca Company Information
  21. 12.4.2 AstraZeneca Business Overview
  22. 12.4.3 AstraZeneca Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  23. 12.4.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  24. 12.4.5 AstraZeneca Recent Developments
  25. 12.5 WAVElife
  26. 12.5.1 WAVElife Company Information
  27. 12.5.2 WAVElife Business Overview
  28. 12.5.3 WAVElife Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  29. 12.5.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  30. 12.5.5 WAVElife Recent Developments
  31. 12.6 Therapeutics
  32. 12.6.1 Therapeutics Company Information
  33. 12.6.2 Therapeutics Business Overview
  34. 12.6.3 Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  35. 12.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  36. 12.6.5 Therapeutics Recent Developments
  37. 12.7 The WhiteOak Group, Inc.
  38. 12.7.1 The WhiteOak Group, Inc. Company Information
  39. 12.7.2 The WhiteOak Group, Inc. Business Overview
  40. 12.7.3 The WhiteOak Group, Inc. Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  41. 12.7.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  42. 12.7.5 The WhiteOak Group, Inc. Recent Developments
  43. 12.8 Sylentis
  44. 12.8.1 Sylentis Company Information
  45. 12.8.2 Sylentis Business Overview
  46. 12.8.3 Sylentis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  47. 12.8.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  48. 12.8.5 Sylentis Recent Developments
  49. 12.9 Sirnaomics
  50. 12.9.1 Sirnaomics Company Information
  51. 12.9.2 Sirnaomics Business Overview
  52. 12.9.3 Sirnaomics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  53. 12.9.4 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  54. 12.9.5 Sirnaomics Recent Developments
  55. 12.10 Silence
  56. 12.10.1 Silence Company Information
  57. 12.10.2 Silence Business Overview
  58. 12.10.3 Silence Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  59. 12.10.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  60. 12.10.5 Silence Recent Developments
  61. 12.11 Secarna
  62. 12.11.1 Secarna Company Information
  63. 12.11.2 Secarna Business Overview
  64. 12.11.3 Secarna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  65. 12.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  66. 12.11.5 Secarna Recent Developments
  67. 12.12 Sarepta Therapeutics
  68. 12.12.1 Sarepta Therapeutics Company Information
  69. 12.12.2 Sarepta Therapeutics Business Overview
  70. 12.12.3 Sarepta Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  71. 12.12.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  72. 12.12.5 Sarepta Therapeutics Recent Developments
  73. 12.13 Quark Pharmaceuticals
  74. 12.13.1 Quark Pharmaceuticals Company Information
  75. 12.13.2 Quark Pharmaceuticals Business Overview
  76. 12.13.3 Quark Pharmaceuticals Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  77. 12.13.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  78. 12.13.5 Quark Pharmaceuticals Recent Developments
  79. 12.14 ProQR
  80. 12.14.1 ProQR Company Information
  81. 12.14.2 ProQR Business Overview
  82. 12.14.3 ProQR Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  83. 12.14.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  84. 12.14.5 ProQR Recent Developments
  85. 12.15 Miragen Therapeutics
  86. 12.15.1 Miragen Therapeutics Company Information
  87. 12.15.2 Miragen Therapeutics Business Overview
  88. 12.15.3 Miragen Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  89. 12.15.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  90. 12.15.5 Miragen Therapeutics Recent Developments
  91. 12.16 Ionis
  92. 12.16.1 Ionis Company Information
  93. 12.16.2 Ionis Business Overview
  94. 12.16.3 Ionis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  95. 12.16.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  96. 12.16.5 Ionis Recent Developments
  97. 12.17 Genzyme
  98. 12.17.1 Genzyme Company Information
  99. 12.17.2 Genzyme Business Overview
  100. 12.17.3 Genzyme Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  101. 12.17.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  102. 12.17.5 Genzyme Recent Developments
  103. 12.18 Exicure
  104. 12.18.1 Exicure Company Information
  105. 12.18.2 Exicure Business Overview
  106. 12.18.3 Exicure Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  107. 12.18.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  108. 12.18.5 Exicure Recent Developments
  109. 12.19 Dicerna
  110. 12.19.1 Dicerna Company Information
  111. 12.19.2 Dicerna Business Overview
  112. 12.19.3 Dicerna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  113. 12.19.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  114. 12.19.5 Dicerna Recent Developments
  115. 12.20 Avidity Biosciences
  116. 12.20.1 Avidity Biosciences Company Information
  117. 12.20.2 Avidity Biosciences Business Overview
  118. 12.20.3 Avidity Biosciences Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  119. 12.20.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  120. 12.20.5 Avidity Biosciences Recent Developments
  121. 12.21 Arrowhead
  122. 12.21.1 Arrowhead Company Information
  123. 12.21.2 Arrowhead Business Overview
  124. 12.21.3 Arrowhead Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  125. 12.21.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  126. 12.21.5 Arrowhead Recent Developments
  127. 12.22 Alnylam
  128. 12.22.1 Alnylam Company Information
  129. 12.22.2 Alnylam Business Overview
  130. 12.22.3 Alnylam Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  131. 12.22.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  132. 12.22.5 Alnylam Recent Developments
  133. 12.23 Akcea
  134. 12.23.1 Akcea Company Information
  135. 12.23.2 Akcea Business Overview
  136. 12.23.3 Akcea Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2021-2026)
  137. 12.23.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product Portfolio
  138. 12.23.5 Akcea Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst